Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares

Rhea-AI Filing Summary

Myriad Genetics director S. Louise Phanstiel reported open‑market purchases of a total of 104,507 shares of common stock across three days. She bought 6,100 shares on February 25 at $4.736 per share, 50,407 shares on February 26 at $4.803 per share, and 48,000 shares on February 27 at $4.661 per share.

The reported prices are weighted averages for multiple trades executed within disclosed intraday ranges. After these transactions, she held 281,951 shares directly and 33,119 shares indirectly through The Phanstiel Trust.

Insider Trade Summary

Net Buyer: 104,507 shares ($494,722)

Net Buy 4 txns

Insider Phanstiel S. Louise

Role Director

Bought 104,507 shs ($495K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	48,000	$4.661	$224K
Purchase	Common Stock	50,407	$4.803	$242K
Purchase	Common Stock	6,100	$4.736	$29K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 281,951 shares (Direct); Common Stock — 33,119 shares (Indirect, The Phanstiel Trust)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.725 to $4.75, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.71 to $5.01, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.79, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Phanstiel S. Louise

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		P		6,100	A	$4.736(1)	183,544	D
Common Stock	02/26/2026		P		50,407	A	$4.803(2)	233,951	D
Common Stock	02/27/2026		P		48,000	A	$4.661(3)	281,951	D
Common Stock								33,119	I	The Phanstiel Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.725 to $4.75, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.71 to $5.01, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.79, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	By: Justin Hunter For: S. Louise Phanstiel	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock purchases did MYGN disclose for S. Louise Phanstiel?

MYGN disclosed that director S. Louise Phanstiel bought 104,507 Myriad Genetics common shares in open-market transactions over three days, with individual trades on February 25, 26, and 27, 2026 at weighted-average prices between $4.661 and $4.803 per share.

On what dates did the MYGN director buy shares and at what prices?

Phanstiel purchased 6,100 shares on February 25 at $4.736, 50,407 shares on February 26 at $4.803, and 48,000 shares on February 27 at $4.661. Each reported price represents a weighted average of multiple trades within specified intraday price ranges.

How many MYGN shares does S. Louise Phanstiel own after these transactions?

After these transactions, Phanstiel directly owned 281,951 Myriad Genetics common shares and indirectly held 33,119 shares through The Phanstiel Trust. These totals reflect her updated beneficial ownership as reported in the Form 4 filing following the February 2026 purchases.

Were the MYGN director’s February 2026 transactions open-market purchases?

Yes. All three reported transactions are coded as open-market or private purchase transactions in common stock, identified with transaction code “P.” The filing describes them as purchases in the open market or private transactions at weighted-average prices within disclosed price ranges.

What do the weighted-average prices in the MYGN Form 4 mean?

The weighted-average prices mean each reported per-share price combines multiple trades executed that day. Footnotes state shares were bought in several transactions within specific price ranges, and the reporting person will provide detailed trade breakdowns upon request to the company, shareholders, or SEC staff.